Glaukos (NYSE:GKOS) Director Gilbert Kliman Sells 5,000 Shares

Glaukos Corporation (NYSE:GKOS) Director Gilbert Kliman sold 5,000 shares of the stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $140.76, for a total value of $703,800.00. Following the completion of the transaction, the director owned 35,528 shares in the company, valued at $5,000,921.28. The trade was a 12.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Glaukos Trading Down 1.1%

GKOS traded down $1.58 during mid-day trading on Monday, reaching $142.43. The stock had a trading volume of 814,291 shares, compared to its average volume of 799,557. The stock has a market capitalization of $8.37 billion, a P/E ratio of -43.42 and a beta of 0.94. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.73 and a current ratio of 5.43. The firm’s fifty day simple moving average is $117.71 and its two-hundred day simple moving average is $112.10. Glaukos Corporation has a 52 week low of $73.16 and a 52 week high of $148.11.

Glaukos (NYSE:GKOS) last announced its quarterly earnings data on Wednesday, April 29th. The medical instruments supplier reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.12. The firm had revenue of $150.57 million for the quarter, compared to analyst estimates of $137.00 million. Glaukos had a negative return on equity of 6.92% and a negative net margin of 34.34%.The business’s quarterly revenue was up 41.2% compared to the same quarter last year. During the same period last year, the company earned ($0.22) EPS. On average, equities analysts predict that Glaukos Corporation will post -0.57 EPS for the current year.

Analysts Set New Price Targets

GKOS has been the topic of a number of recent research reports. BTIG Research increased their price objective on Glaukos from $131.00 to $141.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. Citigroup increased their price target on Glaukos from $135.00 to $140.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. Wells Fargo & Company increased their price target on Glaukos from $135.00 to $138.00 and gave the company an “overweight” rating in a research note on Thursday, April 30th. William Blair raised Glaukos to a “strong-buy” rating in a research note on Friday, January 30th. Finally, Stifel Nicolaus set a $170.00 price target on Glaukos in a research note on Thursday, April 30th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $144.42.

Institutional Trading of Glaukos

Hedge funds have recently added to or reduced their stakes in the business. First Horizon Corp raised its stake in Glaukos by 1,715.4% during the 4th quarter. First Horizon Corp now owns 236 shares of the medical instruments supplier’s stock worth $27,000 after buying an additional 223 shares during the period. Los Angeles Capital Management LLC acquired a new stake in Glaukos during the 4th quarter worth $28,000. UMB Bank n.a. raised its stake in Glaukos by 102.6% during the 3rd quarter. UMB Bank n.a. now owns 312 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 158 shares during the period. Larson Financial Group LLC raised its stake in Glaukos by 62.0% during the 4th quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier’s stock worth $39,000 after buying an additional 132 shares during the period. Finally, Parallel Advisors LLC raised its stake in Glaukos by 159.2% during the 1st quarter. Parallel Advisors LLC now owns 368 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 226 shares during the period. Institutional investors and hedge funds own 99.04% of the company’s stock.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.